Profound MedicalPROF
Recorded

Profound Medical Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Rick WiseManaging Director

Here we are for our next session. Rick Wise here, welcoming management of Profound, and we have got the full complement. Founder, CEO, resident guru, Arun Menawat, who sadly, happily, probably for you, has announced at a very tender age, actually, I am not going to say your age, at a very tender age, is going to be moving into the Executive Chairman role. Richard Fabian, who has been here for a while, is moving into, is it just Chief Executive Officer as of January- 14th 14th, your birthday, everyone's birthday.

Rick WiseManaging Director

Matthew Sobczyk, here, I think you have been at the firm quite a while, but now will be Chief Financial Officer. Welcome to you all. Thank you for being here.

Rick WiseManaging Director

Thank you. Appreciate it. Take us away.

Richard FabianPresident and Incoming CEO

Thank you, Rick, and we appreciate the invitation to be at the Stifel Conference and present our story. I won't go through it, but of course, here's our standard forward-looking statement. Of course, Profound has two platforms that you may be aware of. One is our TULSA-PRO, that's our flagship. We also have our Sonalleve business, and we're going to focus over the next 20 minutes or so on the TULSA-PRO for this purpose. If you take a look at the market opportunity, we kind of have two buckets. One is PCA, the other is on the BPH side. If we take a look at the PCA side, what this research shows is about 85% of that is multifocal. As you can see, very few, about 15% is monofocal, and that's what the data says.

Richard FabianPresident and Incoming CEO

Of course, that's what you can see when you come up with that study. We all know that what you see is not always what's out there when it comes to prostate cancer. The addressable cases annually are about 200,000 for PCA, about 400,000 addressable cases for BPH. I wanted to mention that there are still roughly 3.5 million patients under active surveillance. So those are people that have been diagnosed with early-stage prostate cancer and not being treated. It's one of the few, I believe it's the only cancer that has active surveillance, and where once you have it, you don't necessarily treat it until it gets worse. However, if we take a look at our average procedure price of roughly $8,000, we're looking at between PCA and BPH, roughly a $5 billion addressable market in the U.S. alone. So quite a big market. Here's the procedure. You can see this is in bore, in the MRI, and what's kind of remarkable about this procedure as you take a look, we talk about incisionless surgery.

Richard FabianPresident and Incoming CEO

Well, that's what this is. This is also using the precision of an MRI. What that allows you to do is leverage AI for planning real-time MRI guidance, as well as thermometry, so you can see exactly the region where you're ablating real time. Closed-loop control, robotic precision during this, and protects the critical structures outside of the region that you are trying to ablate. This is a really important slide if you take a look at the unique difference of where TULSA fits in this continuum. You have either whole gland treatment all the way to the left, robotic laparoscopy, prostatectomy, and radiation. To the right, you have focal therapies, which are really focused on spot treatment.

Richard FabianPresident and Incoming CEO

In the middle, you have TULSA, which does everything from focal to whole gland and everything in between. I think, and you can see from the whole gland image all the way to partial gland, we are the only solution that can really flex between the entire spectrum of cancers. Energy matters. When you start to think about how gentle the energy source is and how specific the delivery is, it's absolutely incredible. We use far less energy than HIFU or histotripsy. You can see we heat to 57 degrees Celsius. That is the kill zone. So that's the specific temperature we heat to. If you start to think about energy being put into the body at a much higher level and potentially impacting other areas outside of the targeted area and the damage that can be done.

Richard FabianPresident and Incoming CEO

We can go directly up to the margins because of the targeted energy that we are using. It kills more gently in the targeted tissue faster. You can see that we ablate at one to two ccs per minute. HIFU is about a tenth of that per minute. It is a much faster and gentler way to target the tissue. The other thing is that TULSA ablation leads to tissue shrinkage and absolutely kills cell DNA, and you can see that in these images. You can see it in the MRI as you follow up that the tissue has been killed and the body processes and disposes of that.

Richard FabianPresident and Incoming CEO

I won't go through all the AI innovation, but the fact that our primary users are urologists who, by definition, have not been trained on MR and MR surgery, the fact that we have leveraged AI to make life easier for the urologist, I think it is a perfect platform to do that. You can see, I will focus on number 2, which is the Contouring Assistant. The manual contouring is very time-consuming and repetitive and operator-dependent. We partnered with the top radiologists to create the AI using thousands and thousands of images, and what you will see is that the Contouring Assistant, it is extremely fast, superior to urologists, as well as similar to the best experts in radiology. That is something that as soon as the MRI is done, the urologist has the ability to review and either accept or change the margins that the AI is recommending for that.

Richard FabianPresident and Incoming CEO

We have over 70 peer-reviewed publications and 200-plus clinical presentations. I think the interesting thing about the presentations, and I think you will see the excitement about what we are doing, is the fact that, again, going back to everything from focal to salvage to whole gland, we have done the research. We have been partnering with the top clinical institutions to come up with peer-reviewed publications in this area. The other thing, if you notice on this graphic, is you can see the margins that have been outlined and how specific and how well the TULSA Procedure allows you to target the area that you are intending to kill. This is a great graphic because if you take a look at this, you will see to the left, how would you like to do a procedure? Sitting down at a control panel.

Richard FabianPresident and Incoming CEO

In this particular case, Dr. Klotz and Dr. Emberton are having a discussion as they are watching the TULSA Procedure. It looks like Dr. Klotz might be eating an apple and relaxing as the procedure is going on. Over to the right, as you are doing the robotic prostatectomy, you will see the kind of hectic environment of that procedure with a lot of staff members around the patient. I think the interesting thing about this is also when you start taking a look at the future and the desire for new concepts like telesurgery. This is right outside in the control room of the MRI.

Richard FabianPresident and Incoming CEO

What stops somebody from thinking about having the MRI in a different location, either in the same city, a different location, in a different state, perhaps a different country, and being able to have the control panel where the physician is guiding a surgery wherever it is? As we take a look at the future, there are huge potentials. The other thing is just the efficiency, scalability, and versatility of this system, being able to do a prostate cancer case, going right to a BPH case, and continuing to just do more and more cases as this scales. We use metrics. We are a metric-driven organization. I think in healthcare, you have to be. What is really interesting about this is the most recent quarter.

Richard FabianPresident and Incoming CEO

You will see that the versatility that this 98% patients underwent ablation of prostate tissue, and you will see that we really have tremendous breadth in what we are doing, including the prostate size, the regional ablation of malignant prostate tissue, prostate condition. We really do it all. The money slide. I think when you start taking a look at the reimbursements, they have been exceptional for the procedure. A lot of times you think of the MRI, especially in a diagnostic setting, as being a cost center. The better utilization of the MRI for procedures is also something that is great for patient care, great for the hospitals, and also creates revenue for the MRI that are fixed assets at the hospital. You can see the hospital payments that currently exist.

Richard FabianPresident and Incoming CEO

ASC, we just got very favorable news from CMS on the reimbursement the other week, I think a week and a half ago, on that. You can see the physician payment to 90 days is about the same as other procedures, and physician office payment is also quite strong. So across the board, reimbursements have been very, very strong for TULSA procedures. Utilization is growing. I think this is exciting. A year ago, or two years ago, in 2024, we had 59 placements. Last year, 70. The quarter that just ended, September 30th, we are up to 98 systems. We are in top-tier hospitals in the U.S., as well as on a global basis. Early adopters and independent centers are also very interested in growing as well. I think this also shows the utilization growing year over year.

Richard FabianPresident and Incoming CEO

Two years ago, 2024, we were at $10 million, going up last year, growing to $16 million, and our current guidance for the year is $25 million or greater, as we head into the final quarter of 2026. The margins have been improving. If you take a look, traditionally in med tech, 66% is pretty good. Last year was 70.8%. This year, we are on target for over 75%, including last quarter, where margins were over 78%. We are really excited about the CAPTAIN trial. We released, back in the summer, the first 90 days at RSNA. At the end of this month, early December, we are going to be launching our full-year results on the CAPTAIN trial. Across the board, you will see that this has been a tremendously successful trial for us, comparing whole gland ablation versus robotic radical prostatectomy.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day